Case Details
- Citation: [2021] SGCA 111
- Case Title: Noor Azlin bte Abdul Rahman and another v Changi General Hospital Pte Ltd
- Court: Court of Appeal of the Republic of Singapore
- Date of Decision: 29 November 2021
- Coram: Andrew Phang Boon Leong JCA; Judith Prakash JCA
- Case Number: Civil Appeal No 39 of 2021
- Procedural Posture: Appeal limited to the High Court’s quantification of damages and costs following remittal
- Plaintiff/Applicant: Noor Azlin bte Abdul Rahman (first appellant); Azmi Bin Abdul Rahman (second appellant, as executor/estate representative)
- Defendant/Respondent: Changi General Hospital Pte Ltd (“CGH”)
- Legal Areas: Damages – Assessment; Damages – Quantum; Damages – Measure of damages (personal injuries; life expectancy; pain and suffering; loss of earnings; aggravated and punitive damages)
- Key Holding on Liability (from earlier decision): CGH breached its duty of care by delaying diagnosis of lung cancer, causing progression from stage I to stage IIA and subsequent growth and metastasis
- High Court Decision Under Appeal: Noor Azlin bte Abdul Rahman and another v Changi General Hospital Pte Ltd and others [2021] SGHC 10
- First CA Judgment (liability and remittal): Noor Azlin bte Abdul Rahman v Changi General Hospital Pte Ltd and others [2019] 1 SLR 834 (“the first CA Judgment”)
- Judgment Length (as provided): 57 pages; 33,077 words
- Counsel for Appellants: Vijay Kumar Rai and Jasleen Kaur (Arbiters Inc Law Corporation)
- Counsel for Respondent: Kuah Boon Theng SC, Yong Kailun Karen and Samantha Oei Jia Hsia (Legal Clinic LLC)
- Statutes Referenced: Civil Law Act; Companies Act; Supreme Court of Judicature Act
- Related/Preceding Decisions Mentioned: [2019] 1 SLR 834; [2021] SGHC 10; [2021] 2 SLR 440 (Transfer Judgment); and other cited authorities listed below
Summary
This appeal, CA/CA 39/2021, arose from a long-running medical negligence dispute in which the Court of Appeal had earlier found that Changi General Hospital Pte Ltd (“CGH”) breached its duty of care by delaying the diagnosis of the first appellant, Ms Noor Azlin bte Abdul Rahman (“Ms Azlin”), with lung cancer. The delay caused the cancer to progress from stage I to stage IIA, with subsequent growth of the cancerous nodule and later metastasis. In the first Court of Appeal decision, the court remitted the question of loss and damage, including the quantification of damages (if any), to the High Court for determination.
By the time of the High Court’s assessment, Ms Azlin had passed away from cancer. The High Court found that there was a causal link between CGH’s negligence and Ms Azlin’s death, and awarded damages of $326,620.61 plus $105,000 in costs. On appeal, the Court of Appeal accepted that causation and liability were not in issue. The appeal concerned only the quantification of damages and costs. The Court of Appeal allowed the appeal in part and increased the damages award to $343,020.61, while affirming the $105,000 costs award.
Crucially, the Court of Appeal emphasised that the quantum was “limited” not by the merits of Ms Azlin’s case, but by the way the case was pleaded and evidenced. The court noted significant evidential and pleading deficiencies, including the appellants’ decision to proceed on the basis that Ms Azlin was alive, without seeking leave to amend pleadings to reflect her death, and without calling witnesses to quantify damages despite an earlier remittal order inviting refinement of evidence.
What Were the Facts of This Case?
The factual background is rooted in Ms Azlin’s repeated presentations to CGH’s Accident and Emergency (“A&E”) and specialist services between 2007 and 2011, and the eventual discovery and treatment of lung cancer. On 31 October 2007, Ms Azlin visited CGH’s A&E complaining of lower chest pain and shortness of breath. A chest X-ray (the “October 2007 X-ray”) showed an opacity in the right mid-zone of her chest. She later returned to CGH on three further occasions, during which the opacity was variously treated as resolving, incidental, or associated with a musculoskeletal condition, and follow-up was recommended or arranged.
On 15 November 2007, at CGH’s Specialist Outpatient Clinic (“SOC”), Dr Imran bin Mohamed Noor ordered chest X-rays and assessed that the opacity noted in October 2007 was resolving or had resolved. Ms Azlin was given an open date for follow-up. On 29 April 2010, she returned to A&E with right lower chest pain; Dr Yap Hsiang ordered an X-ray and ECG and treated the opacity as an “incidental finding” because its size remained more or less the same. Dr Yap requested follow-up after the radiological report, if necessary. On 31 July 2011, Ms Azlin again presented with intermittent left lower ribcage pain; Dr Soh Wei Wen Jason ordered X-rays and ECG, and the clinical view was that she had costochondritis. She was discharged with analgesics, though the reports recommended follow-up of the opacity.
On 28 November 2011, Ms Azlin sought care at Raffles Medical Clinic for cough, breathlessness, and blood in sputum. She returned on 1 December 2011 for an X-ray (the “December 2011 X-ray”), which showed a lesion in the right mid-zone of the lung. She was referred to a respiratory physician at CGH’s SOC and was seen on 15 December 2011 by Adjunct Assistant Professor Sridhar Venkateswaran (“Prof Sridhar”). Prof Sridhar ordered a CT scan, which revealed a nodule. A biopsy on 16 February 2012 confirmed malignancy and that Ms Azlin had cancer originating from the nodule.
Ms Azlin’s cancer trajectory is central to the damages assessment. Initially, the stage was not yet known. On 1 March 2012, Prof Sridhar explained that Ms Azlin had a good chance of complete cure with a lobectomy; she was clinically staged as having stage I lung cancer. On 29 March 2012, she underwent a lobectomy and resection of one-third of her right lung. The tumour measured 3.0 cm and was pathologically diagnosed as stage IIA non-small cell lung cancer. She then underwent adjuvant chemotherapy and periodic CT scans. In August 2014, recurrence was discovered and biopsy confirmed progression to stage IV. Later analysis in December 2014 retrospectively identified an ALK-gene arrangement, leading to a retrospective diagnosis of ALK-positive lung cancer in 2012. Ms Azlin was treated with ALK inhibitors and other modalities over subsequent years until her death on 1 April 2019.
What Were the Key Legal Issues?
The principal legal issue on this appeal was not whether CGH was liable, but how damages should be quantified following the High Court’s assessment. The Court of Appeal had already determined in the first CA Judgment that CGH was in breach of duty of care and that the delay caused progression of the cancer. Accordingly, the present appeal was confined to the High Court’s approach to the measure of damages, the quantum awarded under various heads, and the evidential sufficiency supporting those heads.
A second, closely related issue concerned the effect of Ms Azlin’s death on the damages framework. The Court of Appeal observed that the factual and evidential matrix was “fundamentally” altered by her passing. This raised questions about what heads of claim were properly pleaded and proved in light of death, including whether claims such as loss of future earnings and CPF contributions could be pursued without amendment, and whether a claim for loss of inheritance (or other death-related heads) should have been pleaded and evidenced.
Third, the appeal required the court to consider the role of pleading and proof in personal injury damages. The Court of Appeal highlighted that the court is bound to adjudicate on the pleaded claims and the evidence adduced. This meant that even if the underlying negligence was established, the appellants could not recover for heads that were not properly pleaded or for which the necessary evidence was not called or adduced.
How Did the Court Analyse the Issues?
The Court of Appeal began by situating CA 39 as a “sequel” to the first CA Judgment. In that earlier decision, the court had held CGH liable and remitted the question of loss and damage to the High Court. The remittal was specifically intended to allow the parties to refine or revise their evidence. The Court of Appeal then explained that the High Court, after a six-day trial in 2020 (“the AD Hearing”), awarded damages and costs, finding a causal link between CGH’s negligence and Ms Azlin’s death. The present appeal therefore proceeded on the basis that causation and liability were not contested.
However, the Court of Appeal’s analysis turned to the limitations imposed by the way the case was advanced. The court noted that Ms Azlin’s death occurred about a month after the first CA Judgment. The second appellant, her brother, was added as executor to continue the action. Yet, the appellants’ case on appeal was being advanced on the basis that Ms Azlin was alive. The Court of Appeal treated this as a decisive procedural and evidential misalignment: the appellants did not seek leave to amend pleadings to reflect death-related heads of claim, particularly a claim for loss of inheritance. This failure affected the scope of recoverable damages.
The court also emphasised that the appellants did not call witnesses to give evidence on quantification of damages during the AD Hearing, despite the earlier remittal order inviting refinement of evidence. The Court of Appeal considered that the appellants’ confirmation that they would not need witnesses was inconsistent with the evidential needs of the remitted issues. In the court’s view, this contributed to the inability to prove significant portions of the losses claimed. The court further observed that counsel for the appellants had been alerted to these deficiencies well before the AD Hearing, including at the interim payment application hearing in 2019 and at the Judge-led Pre-Trial Conference in November 2019.
In particular, the Court of Appeal recorded that CGH had alerted the appellants to: (a) insufficiency of evidence to support certain pleaded heads, such as out-of-pocket expenses incurred up to Ms Azlin’s death; (b) the need to amend claims in light of her passing, including claims for loss of future earnings and CPF contributions; and (c) the absence of any pleaded claim for aggravated damages. The Court of Appeal treated these as material pleading and proof defects. As a result, the High Court’s quantification could not fully compensate for losses that were not properly proved or pursued.
Against this backdrop, the Court of Appeal reviewed the High Court’s quantification and adjusted the damages award upward from $326,620.61 to $343,020.61. While the extract provided does not reproduce the full breakdown, the Court of Appeal indicated that it provided a table of its award and that certain sections (shown in blue in the judgment) reflected areas where no appeal was brought against the High Court. This suggests a targeted appellate correction rather than a wholesale re-assessment. The court also affirmed the High Court’s award of $105,000 for costs of the AD Hearing, indicating that the procedural and costs aspects were not disturbed.
Finally, the Court of Appeal addressed the tension between legal principle and human tragedy. It acknowledged the enormity of the loss and suffering caused by CGH’s negligence and recognised that the award might appear inadequate compared to the irreversible consequences. Nonetheless, the court reiterated that damages adjudication is governed by pleaded claims and evidence. The burden of proof lies on the party seeking to vindicate the claim, and the court’s role is to apply the law to what is properly pleaded and proved.
What Was the Outcome?
The Court of Appeal allowed CA 39 in part. It increased the appellants’ damages award from $326,620.61 to $343,020.61. The court affirmed the High Court’s award of $105,000 for costs of the AD Hearing.
Practically, the outcome demonstrates that even where liability and causation are established in a medical negligence case, the quantum of damages can be constrained by pleading strategy and evidential choices—particularly where the claimant’s death changes the relevant heads of loss and the evidence required to prove them.
Why Does This Case Matter?
This decision is significant for practitioners because it underscores the procedural discipline required in damages assessment, especially in personal injury and medical negligence litigation. The Court of Appeal’s reasoning makes clear that the court’s quantification exercise is not a free-ranging inquiry into “what happened” but a legal evaluation of what losses are pleaded and proved. Where the claimant’s circumstances change—here, death—parties must promptly align pleadings and evidence with the correct legal heads of claim.
From a precedent perspective, the case reinforces that remittal orders inviting parties to refine evidence must be taken seriously. The Court of Appeal’s criticism of the appellants’ decision not to call witnesses on quantification, despite being alerted to evidential gaps, signals that courts may treat such omissions as fatal to recovery for particular heads. This is especially relevant where damages depend on specific factual inputs, such as out-of-pocket expenses, the timing of incurred losses, and the counterfactual assumptions underlying loss of earnings and related benefits.
For law students and litigators, the case also illustrates how damages in Singapore are structured around legal categories (including pain and suffering, loss of earnings, and potentially aggravated damages where properly pleaded). The decision highlights that aggravated and punitive damages are not recoverable by implication; they require proper pleading and evidential foundation. Overall, the case serves as a cautionary example that the success of a negligence claim does not automatically translate into full recovery of all claimed losses unless the litigation is conducted with careful attention to pleadings, amendments, and proof.
Legislation Referenced
Cases Cited
Source Documents
This article analyses [2021] SGCA 111 for legal research and educational purposes. It does not constitute legal advice. Readers should consult the full judgment for the Court's complete reasoning.